Hyasynth Bio is a biotechnology company specializing in the biosynthesis of cannabinoids, which are compounds found in cannabis plants. The company operates in the pharmaceutical and wellness markets, focusing on producing rare cannabinoids through fermentation technology. This method is more sustainable and scalable compared to traditional plant extraction. Hyasynth Bio serves pharmaceutical companies, wellness product manufacturers, and other industries that require high-quality cannabinoids. The business model revolves around licensing its biosynthesis technology and selling the cannabinoids produced. Revenue is generated through milestone payments, licensing fees, and direct sales of cannabinoids. The company has achieved significant milestones, including the production of 20 rare cannabinoids and securing patents for its technology. Hyasynth Bio is backed by investors like Organigram Holdings Inc., which supports its commercialization efforts.

Keywords: Cannabinoids, Biosynthesis, Fermentation, Pharmaceutical, Wellness, Sustainable, Biotechnology, Licensing, Patents, Organigram.